RYALTRIS 25mcg / 600mcg / dose nasal spray, solution medication leaflet

R01AD59 olopatadine + mometasone • Respiratory system | Decongestants and other nasal preparations for topical use | Corticosteroids

The combination of olopatadine and mometasone is used in the treatment of seasonal or perennial allergic rhinitis. Olopatadine is an antihistamine that reduces allergic symptoms, while mometasone is a corticosteroid that reduces nasal inflammation.

The medication is administered as a nasal spray, as directed by a doctor, usually once or twice daily. It is important for patients to follow the recommended dosage and avoid long-term use without medical supervision.

Patients should be aware of potential side effects, such as nasal irritation, dryness, or nosebleeds. It is important to inform the doctor of any unusual symptoms.

Common side effects include nasal irritation, dryness, and nosebleeds. In rare cases, severe reactions such as nasal infections or allergic reactions may occur. Patients should be informed of these risks before use.

General data about RYALTRIS 25mcg / 600mcg / dose

Substance: olopatadine + mometasone

Date of last drug list: 01-04-2026

Commercial code: W67951003

Concentration: 25mcg / 600mcg / dose

Pharmaceutical form: nasal spray, solution

Quantity: 1

Product type: original

Price: 71.79 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA

Holder: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA

Number: 13994/2021/03

Shelf life: 3 years-after packaging for sale;after the first opening-2 months